Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 131 to 140 of 298 total matches.
Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
of drugs
metabolized by these isozymes, including oral
contraceptives.
Use of mavacamten ...
The FDA has approved mavacamten (Camzyos –
MyoKardia/BMS), a modulator of cardiac myosin, to
improve functional capacity and symptoms in adults
with New York Heart Association (NYHA) class II or
III obstructive hypertrophic cardiomyopathy (HCM)
who have a baseline left ventricular ejection fraction
(LVEF) ≥55%. Mavacamten is the first drug in its class
to become available in the US.
Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
contraception does not qualify for treatment
with the drug.
VULVOVAGINAL CANDIDIASIS — Vulvovaginal ...
The FDA has approved oteseconazole (Vivjoa –
Mycovia), a new oral azole antifungal, to reduce the incidence
of recurrent vulvovaginal candidiasis (RVVC)
in females with a history of RVVC. Oteseconazole is
the first drug to be approved in the US specifically for
treatment of RVVC.
Drugs that Cause Photosensitivity
The Medical Letter on Drugs and Therapeutics • Apr 14, 1995 (Issue 946)
(Atromid-S, and others)
Contraceptives, oral
Desoximetasone (Topicort, and others)
Disopyramide (Norpace ...
As the weather becomes warmer, physicians may see more photosensitivity reactions due to systemic or topical drugs, perfumes, cosmetics or sunscreens. Even brief exposure to sunlight in warm or cold weather can cause intense cutaneous reactions in patients with drug-induced photosensitivity, and some patients may continue to be sensitive to sunlight long after stopping use of the offending agent.
Vandetanib (Caprelsa) for Medullary Thyroid Cancer
The Medical Letter on Drugs and Therapeutics • Jan 09, 2012 (Issue 1381)
(positive evidence
of risk) for use during pregnancy. Women of
child-bearing age should use contraception ...
The FDA recently approved vandetanib [van det´ a nib]
(Caprelsa – AstraZeneca) for oral treatment of symptomatic
or progressive medullary thyroid cancer (MTC) in
patients with unresectable locally advanced or metastatic
disease. Vandetanib is the first drug approved in the
US for medullary thyroid cancer.
Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Sep 16, 2013 (Issue 1425)
of risk) for use during pregnancy.
Women of child-bearing age should use effective contraception
during ...
Ado-trastuzumab emtansine (Kadcyla – Genentech), a
human epidermal growth factor receptor 2 (HER2)-targeted
antibody and microtubule inhibitor conjugate, has
been approved by the FDA for intravenous (IV) treatment
of HER2-positive metastatic breast cancer in
patients previously treated with trastuzumab (Herceptin)
and a taxane. The prefix was added to the new conjugate’s
name at the request of the FDA to distinguish it
from trastuzumab.
Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only)
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017 (Issue 1527)
should use contraception during treatment and
for 3 months after the last dose. Whether olaratumab ...
Olaratumab (Lartruvo – Lilly), a platelet-derived growth
factor receptor alpha (PDGFR-α) blocking monoclonal
antibody, has received accelerated approval from the
FDA for use in combination with the anthracycline
doxorubicin for first-line treatment of adults with
soft-tissue sarcoma histologic subtypes considered
susceptible to anthracyclines. Approval is limited to
locally advanced or metastatic soft-tissue sarcomas
that are not amenable to curative radiotherapy or
surgery, and is contingent on verification of clinical
benefit in a confirmatory phase 3 trial.
Lutetium Lu 177 Dotatate (Lutathera) for Gastroenteropancreatic Neuroendocrine Tumors (online only)
The Medical Letter on Drugs and Therapeutics • Sep 10, 2018 (Issue 1555)
potential and their male partners should use effective
contraception during treatment and for 7 months ...
The FDA has approved lutetium Lu 177 dotatate (Lutathera – Advanced Accelerator Applications), a radiolabeled somatostatin analog, for treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEPNETs) in adults.
Alpelisib (Vijoice) for PIK3CA-Related Overgrowth Spectrum (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
with female
partners of reproductive potential should use effective
contraception during treatment ...
The oral kinase inhibitor alpelisib (Vijoice – Novartis)
has been approved by the FDA for treatment of
patients ≥2 years old with severe manifestations of
PIK3CA-related overgrowth spectrum (PROS) who
require systemic treatment. Alpelisib is the first
drug to be approved in the US for this indication.
It was also approved in 2019 as Piqray for use in
combination with fulvestrant for treatment of certain
types of breast cancer.
In Brief: Zanubrutinib (Brukinsa) for CLL or SLL (online only)
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
contraceptive method while taking
the drug and for 1 week after the last dose. No data
are available ...
The Bruton's tyrosine kinase (BTK) inhibitor
zanubrutinib (Brukinsa), which was previously
approved by the FDA for treatment of mantle cell
lymphoma, Waldenström's macroglobulinemia,
and relapsed or refractory marginal zone
lymphoma, has now been approved for treatment
of chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL) in adults. The BTK
inhibitors ibrutinib (Imbruvica) and acalabrutinib
(Calquence) were approved earlier for treatment of
CLL and SLL.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e33-4 doi:10.58347/tml.2023.1670e | Show Introduction Hide Introduction
In Brief: A Second Indication for Tucatinib (Tukysa) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
at the recommended
dose. Women of reproductive potential and their male
partners should use effective contraception ...
The oral kinase inhibitor tucatinib (Tukysa – Seagen)
has received accelerated approval from the FDA for
use in combination with trastuzumab (Herceptin)
for treatment of adults with RAS wild-type human
epidermal growth factor receptor 2 (HER2)-positive
unresectable or metastatic colorectal cancer
that has progressed following treatment with
fluoropyrimidine-, oxaliplatin-, and irinotecan-based
chemotherapy regimens. Tucatinib was approved in
2020 for use in combination with trastuzumab and
capecitabine (Xeloda, and generics) for treatment
of adults with advanced unresectable or...
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e37-8 doi:10.58347/tml.2023.1670g | Show Introduction Hide Introduction